Key Highlights
- 4.18% is the indicated pre-market gain for PepGen Inc. (NASDAQ:PEPG) on November 19, 2026, taking the price to USD 3.83 from a calculated prior close of USD 3.68, a calculated move of USD 0.15.
- 25 million shares at USD 5.00 each were priced in the public offering announced on November 11, 2026, for expected gross proceeds of USD 125 million, with a 30-day option for up to 3,750,000 more shares.
- 104.8 million USD in cash, cash equivalents and marketable securities was reported at September 30, 2026, which the company says funds operations into 2028, per the third quarter results released on November 10, 2026.
- 46.5% mean splicing correction was reported at week 13 for the 10 mg/kg cohort of the Phase 2 FREEDOM2 trial in myotonic dystrophy type 1.
What Moved PepGen Inc. (NASDAQ:PEPG) in Pre-Market Trading on November 19, 2026 (+USD 0.15, +4.18%)
The indicated pre-market price for PepGen Inc. (NASDAQ:PEPG) is USD 3.83 on November 19, 2026, a pre-market move of +4.18%. The calculated prior close, the November 18, 2026 regular-session close, is USD 3.68 (USD 3.83 divided by 1.0418), and the calculated USD move is +USD 0.15. The pre-market Volume is 14,489 shares, so the indication rests on very thin trading. The indicated price is a calculated 23.4% below the USD 5.00 offering price. On 69.3 million shares outstanding at September 30, 2026, the calculated Market Value is about USD 265 million.
The Rationale: Follow-Through From the USD 125 Million Offering and Trial Update for PepGen Inc. (NASDAQ:PEPG)
No new same-day announcement was identified in published coverage for November 19, 2026, so the move appears to be follow-through from the recent financing and clinical update. As general context, biotech shares often trade below a deal price after a large offering. On November 11, 2026 the company priced 25 million shares at USD 5.00 for expected gross proceeds of USD 125 million. On November 10, 2026 it reported third quarter results and said the 12.5 mg/kg cohort is fully enrolled, with results expected in the first half of 2027. Chief Executive Officer James McArthur said the company is very confident in the potential of PGN-EDODM1.
Valuation, Liquidity and Risks for PepGen Inc. (NASDAQ:PEPG)
Third quarter Research and Development expense was USD 14.5 million, up from USD 13.4 million. The net loss was USD 19.4 million, or USD 0.28 per share, versus USD 18.0 million, or USD 0.52 per share, in the prior-year quarter. Cash of USD 104.8 million plus USD 125 million of expected gross proceeds imply a calculated total near USD 229.8 million before expenses. Risks are specific. The FDA placed a partial clinical hold on the FREEDOM2 study in March 2026, citing nonclinical findings in mice, and the hold remains in place. The lead program has no revenue, and further Equity raises would dilute holders.
Where Things Stand
PepGen Inc. (NASDAQ:PEPG) is indicated up 4.18% in pre-market trading on November 19, 2026, at USD 3.83, a calculated gain of USD 0.15 from a prior close of USD 3.68, on only 14,489 shares of pre-market volume. No new same-day catalyst was identified in published coverage. The backdrop is a USD 125 million public offering priced at USD 5.00 on November 11, 2026, third quarter results with USD 104.8 million in cash and securities, and Phase 2 data showing 46.5% splicing correction at 10 mg/kg. A partial clinical hold, dilution and the lack of Revenue remain key risks, and pre-market indications can reverse at the 9:30 a.m. ET open. This is not Investment advice.






Please wait processing your request...